Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07873047
NA

Acute Effects of Caffeine on Mitochondrial Function in Peripheral Blood Mononuclear Cells

Sponsor: Pontificia Universidad Catolica de Chile

View on ClinicalTrials.gov

Summary

This randomized, double-blind, placebo-controlled crossover study will evaluate the acute effects of caffeine consumption on substrate utilization, resting energy metabolism, and mitochondrial function in peripheral blood mononuclear cells (PBMCs) in healthy young adults. Approximately 10 healthy men and women aged 18 to 35 years will participate. Each participant will complete two experimental visits, receiving caffeine in one visit and placebo in the other, in randomized order. The two visits will be separated by a 48-hour washout period. Participants will attend the laboratory after an overnight fast of approximately 14 hours and will abstain from caffeine, alcohol, and intense physical activity before each visit. Resting gas exchange will be measured before ingestion and 1 and 3 hours after caffeine or placebo administration. Blood samples will be collected at the same time points to isolate PBMCs and obtain plasma for metabolic analyses. Mitochondrial function will be assessed by high-resolution respirometry, and mitochondrial dynamics and morphology will be evaluated using protein analyses and transmission electron microscopy. The study will determine whether acute caffeine consumption alters resting substrate utilization and mitochondrial responses in PBMCs in healthy young adults.

Official title: Efectos Agudos Del Consumo de cafeína en el Uso de Sustratos y en la función Mitocondrial en células Mononucleares de Sangre periférica

Key Details

Gender

All

Age Range

18 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

12

Start Date

2026-09

Completion Date

2027-03

Last Updated

2026-10-14

Healthy Volunteers

Yes

Interventions

DIETARY_SUPPLEMENT

Caffeine (5 mg/kg)

Caffeine will be administered orally as a single weight-adjusted dose of 5 mg/kg body weight in an opaque capsule with approximately 250 mL of water. It will be administered immediately after baseline measurements during one experimental visit. Participants will receive caffeine in one of the two study periods according to the randomized crossover sequence. Resting gas exchange and venous blood samples will be collected before ingestion and 1 and 3 hours after ingestion.

OTHER

Placebo

The placebo will consist of an inert substance administered orally in an opaque capsule matched in appearance to the caffeine capsule, with approximately 250 mL of water. It will be administered immediately after baseline measurements during one experimental visit. Participants will receive placebo in one of the two study periods according to the randomized crossover sequence.